Alfuzosin for the management of benign prostate hyperplasia.
Alfuzosin (UroXatral, Sanofi-Synthelabo) a quinazoline derivative, has well-documented alpha(1)-adrenoreceptor antagonist activity. These receptors are present in the smooth muscle located at the bladder base, proximal urethra, prostate and prostatic capsule as well as in vascular and nervous systems. Consequently, alfuzosin has the ability to reduce the tone of these areas, effectively decreasing bladder outlet resistance. A sustained-release formulation of alfuzosin is currently available in Europe and is FDA-approved in the US. The confirmed efficacy, proven bioavailability and good cardiovascular safety profile support the use of this drug for the management of lower urinary tract symptoms secondary to benign prostate hyperplasia (BPH). These findings have been confirmed in a large cohort of patients treated in general practice. Additionally, treatment with alfuzosin has demonstrated a favourable impact on quality of life of patients with BPH.
Weiner
David M
DM
Urology, Columbia University College of Physicians and Surgeons, 425 West 59th Street Suite 3A, New York, NY 10019, USA. dmwess@msn.com
Lowe
Franklin C
FC
D000317:Adrenergic alpha-Antagonists / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D006801:Humans; D008297:Male; D011358:Product Surveillance, Postmarketing; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011799:Quinazolines / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; C047638:alfuzosin